SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for PC: what happened in the last 20 years? J Urol 2004; 172: 1297301
  • 2
    Carvalhal GF, Daudi SN, Kan D et al. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology 2010; 76: 10726
  • 3
    Stamey TA, Freiha F, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71 (Suppl.): 9338
  • 4
    Stamey TA, Kabalin JN, McNeal JE et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 107683
  • 5
    Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 17927
  • 6
    Suardi N, Capitanio U, Chun FK et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 2008; 113: 206862
  • 7
    Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 2009; 181: 162834
  • 8
    Epstein JI, Chan DW, Sokoll LJ et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 160: 240711
  • 9
    Wolters T, Roobol MJ, van Leeuwen PJ et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011; 185: 1215
  • 10
    Morgan R, Boxall A, Bhatt A et al. Engrailed-2 (EN2): a tumour specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res 2011; 17: 10908
  • 11
    D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 96974
  • 12
    Epstein JI. Prognostic significance of tumour volume in radical prostatectomy and needle biopsy specimens. J Urol 2011; 186: 7907
  • 13
    Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumour extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 36874
  • 14
    Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994; 152: 171420
  • 15
    Srigley JR, Amin MB, Bostwick DG et al. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000; 124: 10349
  • 16
    Salomon L, Levrel O, Anastasiadis AG et al. Prognostic significance of tumour volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 2003; 43: 3944
  • 17
    Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395400
  • 18
    Ross AE, Loeb S, Landis P et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 281016
  • 19
    Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004; 171: 15204
  • 20
    Epstein JI, Walsh PC, Carter B. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. JUrol 2001; 166: 168891
  • 21
    Quintal MM, Meirelles LR, Freitas LL et al. Various morphometric measurements of cancer extent on needle prostatic biopsies: which is predictive of pathologic stage and biochemical recurrence following radical prostatectomy? Int Urol Nephrol 2011; 43: 697705
  • 22
    Ploussard G, Durand X, Xylinas E et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011; 59: 4229
  • 23
    Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 molecular urine assay correlates with prostate cancer tumour volume: implication in selecting candidates for active surveillance. J Urol 2008; 179: 1804
  • 24
    Whitman EJ, Groskopf J, Ali A et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumour volume. J Urol 2008; 180: 19759
  • 25
    van Gils MP, Hessels D, Hulsbergen CA et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008; 68: 121522
  • 26
    Hessels D, van Gils MP, van Hooij O et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010; 70: 1016
  • 27
    Auprich M, Chun FK, Ward JF et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011; 59: 96105